肝脏X受体激动剂研究进展  

Research progress of liver X receptor agonists

作　　者：梁瑜[1] 郭长彬[1] 张冲[1] 侯振更[1] 

机构地区：[1]首都师范大学化学系,北京100048

出　　处：《药学学报》2012年第4期427-433,共7页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金资助项目(30873140);北京市优秀人才培养资助项目(20071D0501600227);北京市教委科技发展项目(KM201010028011)

摘　　要：肝脏X受体(LXR)属于核受体超家族成员,对脂肪代谢具有重要调控作用。研究表明LXR激动剂可能作为治疗和预防动脉粥样硬化的潜在药物,已有多个化合物处于临床前评价和生物活性筛选阶段。本文对近年来报道的LXR激动剂进行简要综述。Liver X receptor （LXR）, a member of the superfamily of nuclear receptors, plays an important role in the activation of transcription factors involved in cholesterol metabolism, glucose homeostasis inflammation and lipogenesis. It is shown that LXR agnoists have the potentiality to be used as drugs for the prevention and treatment of atherosclerosis, which is its best investigated therapeutic indication. There are many compounds being studied in preclinical evaluation and biological assay. This paper will review briefly the LXR agonists in recent years.

关 键 词：肝脏X受体 激动剂 动脉粥样硬化 

分 类 号：R916[医药卫生—药学]